Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA305489 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:The immunomodulatory effects of periostin on monocyte-derived macrophages
| PRJNA289646 | ENA
Project description:PPAR/ ligand response in monocyte derived macrophages
2025-01-23 | E-MTAB-3398 | ExpressionAtlas
Project description:The immunomodulatory effects of soluble receptor of activated nuclear factor kappa ligand (sRANKL) on monocyte-derived macrophages
| PRJNA293673 | ENA
Project description:Identification of IL-1 and IL-6-responsive genes in human monocyte-derived macrophages
| PRJNA101635 | ENA
Project description:Expression data from human monocyte-derived dendritic cells treated or not with interleukin 17A (IL-17A)
2025-01-24 | E-GEOD-53163 | ExpressionAtlas
Project description:Affymetrix microarray of human monocyte derived macrophages following challenge with Streptococcus pneumoniae with or without pneumolysin
2025-01-16 | E-MTAB-9055 | ExpressionAtlas
Project description:Transcription profiling of peripheral blood monocyte derived macrophages treated or not with synthetic REVERB ligand GSK-4112.
2025-01-23 | E-MTAB-6478 | ExpressionAtlas
Project description:RNA-seq of monocyte derived macrophages treated with arachidonic acid and/or interleukin-6 and solvent control
2025-01-16 | E-MTAB-8830 | ExpressionAtlas
Project description:Transcriptional profiling of Homo sapiens inflammatory skin diseases (whole skin biospies): Psoriasis (Pso), vs Atopic Dermatitis (AD) vs Lichen planus (Li), vs Contact Eczema (KE), vs Healthy control (KO) In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/TNFα-associated genes specifically expressed in psoriasis, among which IL-36γ was the most outstanding marker. In subsequent immunohistological analyses IL-36γ was confirmed to be expressed in psoriasis lesions only. IL-36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFα-treatment. Furthermore, IL-36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36γ might also provide a future drug target, due to its potential amplifier role in TNFα- and IL-17 pathways in psoriatic skin inflammation. In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/TNFα-associated genes specifically expressed in psoriasis, among which IL-36γ was the most outstanding marker. In subsequent immunohistological analyses IL-36γ was confirmed to be expressed in psoriasis lesions only. IL-36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFα-treatment. Furthermore, IL-36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36γ might also provide a future drug target, due to its potential amplifier role in TNFα- and IL-17 pathways in psoriatic skin inflammation.
2014-12-02 | GSE63741 | GEO
Project description:Transcriptional profiling of human monocyte-derived macrophages
| PRJNA260685 | ENA